Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you look at the...
Published:
Last Updated:
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) is living up to why we just said it is now an overvalued biotech stock for 2013. Biogen Idec and the other biotech giants had risen perhaps too much in...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall St. research firms this Thursday. Alcatel-Lucent S.A. (NYSE: ALU) raised to Neutral from Sell at Credit...
Published:
Last Updated:
Jon OggThe largest biotech stocks have been great performers in 2012. The question is whether that can be sustained in 2013. If Wall St. analysts are correct, biotech and biohealth investors are...
Published:
Last Updated:
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) has had a great 2012. Actually, it has had a hell of a year with a gain of almost 40% year to date. When you compare this to the iShares Nasdaq...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Thursday. Altera Corp. (NASDAQ: ALTR) started at Neutral at SunTrust Robinson Humphrey....
Published:
Last Updated:
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena...
Published:
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals...
Published:
Last Updated:
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Friday. Applied Materials Inc. (NASDAQ: AMAT) maintained Buy with $16 target after...
Published:
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement date....
Published:
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Wednesday. Amgen Inc. (NASDAQ: AMGN) cut to Neutral at R.W. Baird. Automatic Data...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Monday. Advanced Micro Devices Inc. (NYSE: AMD) raised to Neutral from Sell at...
Published:
Last Updated:
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short...
Published: